Results for the First Quarter 2020

Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

Read more

Annual Report 2019

We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

Read more

The REQUEST study is now published

The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

Read more

MiraQ approved for sale in Canada

MiraQ™ is Medistim's newest generation of products for quality assurance within  vascular and cardiac surgery. The system is based on ultrasound, and combines quantitative blood flow volume through transit time flow measurement (TTFM)  with morphological…

Read more

Results for the Third Quarter 2019

Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 %  growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…

Read more